Navigation Links
Study finds plasmin -- delivered through a bubble -- more effective than tPA in busting clots
Date:5/15/2013

CINCINNATIA new study from the University of Cincinnati has found that, when delivered via ultrasound, the natural enzyme plasmin is more effective at dissolving stroke-causing clots than the standard of care, recombinant tissue plasminogen activator (rt-PA).

The novel delivery method involved trapping plasmin into bubble-like liposomes, delivering them to the clot intravenously and bursting it via ultrasound. That method is necessary, says UC associate professor of emergency medicine George "Chip" Shaw III, MD, PhD, because plasmin cannot be delivered through traditional methods. Intravenous delivery of rt-PA is designed to solve that problem by catalyzing the conversion of existing plasminogen inside the body to plasmin, which in turn degrades blood clots.

"Plasmin is the enzyme that actually chews up the fibrin in clots," says Shaw. "The problem is you can only give plasmin inter-arterially, which has safety risks and takes longer to deliver. IV therapy is always easier and quicker, but if you give plasmin intravenously, the body inhibits it immediately. If you can encapsulate it, it doesn't get inhibited and you can target it to the clot."

In their in-vitro study, Shaw and researchers Madhuvathi Kandadai, PhD, and Jason Meunier, PhD, enclosed plasmin and a gas bubble inside a liposome. They then delivered the liposome to a clot in an in-vitro lab clot model and dissolved it using ultrasound waves, thus delivering the plasmin enzyme to the clot. After 30 minutes, clots treated with plasmin showed significantly greater breakdown than clots treated with rt-PA.

They worked with colleague Christy Holland, PhD, professor in UC's cardiovascular diseases division, to develop the technique. As director of the Image-guided Ultrasound Therapeutics Laboratories at UC, Holland has studied the use of liposomes and ultrasound to deliver drugs in a less invasive, more targeted fashion.

The standard of care for acute ischemic stroke is intravenous delivery of U.S. Food and Drug Administration-approved rt-PA within three hours of stroke onset. Ischemic stroke is the most common type of stroke, accounting for about 87 percent of all stroke cases.

But Shaw says there is a "critical need" for a safer and more effective thrombolytic, as rt-PA carries a risk of bleeding. Intracranial hemorrhage currently occurs in 6 percent of patients receiving rt-PA therapy.

"Previous in vivo studies have demonstrated better safety of plasmin as compared with rt-PA," he says. "Currently, intra-arterial plasmin is undergoing clinical trials. Our next step is to work on targeting the liposome by putting antibodies on its surface that will stick it to the clot. We also want to improve the efficiency of encapsulating the plasmin in the liposome. Right now, about 15 percent of the plasmin gets into the liposomewe're aiming for 50 percent."


'/>"/>

Contact: Katy Cosse
kcosse@gmail.com
513-309-3180
University of Cincinnati Academic Health Center
Source:Eurekalert

Related biology technology :

1. Study: FOLFIRINOX Followed by Chemoradiation Shows Substantial Activity in Locally Advanced Pancreatic Cancer
2. Preclinical study shows heroin vaccine blocks relapse
3. New Study on Cordyceps Sinensis (Hirsutella Sinensis) Shows Anti-Inflammatory Properties
4. New Study: Valtrex (Valacyclovir) Side Effects Target the Brain; polyDNA Suggests a Natural Herpes Remedy
5. Wysebridge Patent Bar Review Launches America Invents Act (AIA) Study Suite
6. Breath study brings roadside drug testing closer
7. Japan Bioinformatics Announces Release of a Case Study on Detecting SNPs and Short INDELs
8. Research Foundations Collaborate To Fund Phase 1 Study Of Cancer Drug In Alzheimers Disease Patients
9. Ceregene Reports Data From Parkinsons Disease Phase 2b Study
10. Study Says Kidney Bean Leaves Work Against Bed Bugs, My Cleaning Products Compares Its With a Non-Pesticide Bed Bug Spray
11. NeuroDerm Announces Enrollment in a Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 21, 2017 , ... Beaker, ... executive talent in the life sciences industry, today announces a strategic partnership with ... partnership takes full advantage of Beaker’s expertise in executive recruitment solutions, providing Alcami ...
(Date:6/22/2017)... ... , ... Building on the success of the inaugural RAADfest last year, RAADfest ... developments in radical life extension. RAADfest combines cutting edge science presented for a lay ... development, making it the largest most comprehensive and inclusive super longevity event in the ...
(Date:6/22/2017)... ... June 22, 2017 , ... Ovation Fertility supports the ... disease, bringing new hope for prospective parents who are challenged with costs of ... the World Health Organization’s designation in hopes of changing the way health insurers, ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... to clients throughout the biopharma and life sciences industries, continue to be in ... seeing. Tunnell’s Kip Wolf will be speaking on “The State of Information Governance ...
Breaking Biology Technology:
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
Breaking Biology News(10 mins):